The stimulatory effect of OM-853 (10-7 M) on [14C]5-HT release was antagonized by 10-7 M 8-hydroxy DPAT, which is known to act at presynaptic 5-HT autoreceptors as an agonist. These results suggest that OM-853 may induce facilitation of 5-HT turnover by enhancing 5-HT release, probably via the inhibition of presynaptic 5-HT autoreceptor.
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Materials and Methods
Animal used: Male Wistar rats (180-230 g) were used. A standard chow diet and tap water were made available ad libitum. Ex periments were routinely initiated at 10:00 a.m. to avoid possible circadian variations in the function of cerebral 5-HT neurons.
Drug treatments: OM-853 (Tokyo Tanabe Co., Ltd.) was dissolved in distilled water and administered orally in a volume of 1 ml per 100 g body weight. Experimental animals received 200 mg/kg of OM-853, while the same volume of vehicle was given to the control animals. One hour after the oral administration of OM-853, rats were killed by focussed microwave irradiation (5 kW, for 0.7 sec) on the head for determining the contents of cerebral 5-HT and its metabolite. On the other hand, animals were killed by decapitation when brains were subjected to enzymatic and receptor assays.
Determinations of cerebral 5-HT and its metabolite:
The brain was dissected on a chilled plastic plate, according to the method of Glowinski and Iversen (6). 5-HT and its metabolite were extracted from brain tissues with 0.05 M perchloric acid containing 3,4 dihydroxybenzylamine (DHBA) as an internal standard.
The contents of 5-HT and its metabolite were determined using a Yanaco L-4000W H PLC with VM D-101 A electro chemical detector and a Yanapack ODS-A reverse-phase column (particle size 10 /em, 25 x 0.4 cm internal diameter) (Yanaco Ltd., Kyoto, Japan), according to the method of Wagner et al. (7) with some modifications. The mobile phase was 0.1 M potassium dihydrogen phosphate/phosphoric acid buffer (pH 3.2) containing 10 ,uM EDTA, 2.5 mM 1 -octanesulfonic acid sodium and methanol (18%). The flow rate of the mobile phase and detector potential were set 1 ml/min and 0.8 V against an Ag/AgCI electrode, respectively.
Enzymatic assays: The activity of tryp tophan hydroxylase (Trp-OH) was assayed fluorometrically by determining the formation of 5-hydroxy-L-tryptophan (5-HTP) from L-tryptophan (8). The activity of monoamine oxidase (MAO) was measured by the oxidation of [2-14C] tryptamine according to the method of Otsuka and Kobayashi (9). Measurements of uptake and release of [14C]5-HT: Freshly prepared striatal tissues were sectioned with a microslicer (DTK 1000, Dosaka EM Co. Ltd.. Kyoto, Japan) at 200 am thickness. Each striata! slice (3-4 mg) was weighed and then placed in a small plastic vessel equipped with nylon mesh at the bottom (10) . The slices were then preincubated for 15 min at 37°C in 5 ml of the following incubation medium: The incubation medium consisted of oxygenated Krebs-Ringer bicarbonate buffer (pH 7.4) containing 105 mM NaCI, 4.2 mM KCI, 2.2 mM CaCI2.2H20, 1.0 mM KH2PO4, 1.0 MM MgSO4.7H2O, 25 mM NaHC03, 10 mM D glucose, 0.1 mM ascorbic acid and 20 ,uM pargyline. Following the preincubation, the slice was incubated for 1 5 min in 1 m! of the incubation medium containing 0.1 ,uM [14C] 5-HT. The reaction was terminated by adding 3 ml of the ice-cold medium, and the slice was rinsed twice with 1.5 ml of the ice-cold medium. The radioactivity in the tissue, solubilized with 0.2 ml of 1 M Hyamine IOX OH, was measured using Triton-toluene scintillant (0.5% 2,5-diphenyloxazole (PPO), 0.03% 1,4-di (2-(5-phenyloxazolyl) benzene (POPOP) and 33% Triton X-100 in toluene) and a Packard 3379 liquid scintillation spectrometer.
In the case of the measurement of [14C]5 HT release, the slice was incubated for 30 min in 1 ml of the medium containing 0.1 aM [14C]5-HT. The preloaded slice was rinsed twice with 1.5 ml of the medium, and the vessel containing the slice was transferred successively to vials containing 1.0 ml of the medium at 2 min interval. During the slow phase of [14C]5-HT release (following 16 min of succesive incubations at 2 min inter vals), the slice was stimulated for 2 min by the addition of 30 mM KCI. The radioactivities in each vial and the tissue were measured using the same liquid scintillation spectrom eter as described above. The net uptake of [14C]5-HT was estimated by subtracting the blank value in the presence of 1.0 mM 5-HT, and data for the release of [14C]5-HT were expressed as percentage release [100xradio activity released during 2 min/(total radio activity released+ radioactivity remaining in the tissue)]
and subjected to a compart mental analysis by the "peeling off" technique for the determination of the rate constant (RC) and half time (T1/2) (11, 12 by a rapid vacuum filtration through a Whatman glass filter (GF/ B). Following the rinsing of each filter 3 times with 5 ml of 50 mM Tris-HCI buffer, the washed filter was placed in a vial containing 10 ml Triton-toluene scintillant and subjected to the measurement of radioactivity using a liquid scintillation spectrometer.
The specific binding of each ligand was calculated by subtracting the nonspecific binding from each experimental value. (Fig. 1) .
Effect of OM-853 administration on the activity of enzymes involved in 5-HT syn thesis and degradation: Single administration of OM-853 (200 mg/kg) had no significant effect on the activity of Trp-OH, a rate limiting enzyme for 5-HT synthesis, as well as on that of MAO in all brain areas examined.
Effect of OM-853 on uptake and release of [14C]5-HT in striatal slices: In vitro addition of OM-853 inhibited [14C] 5-HT uptake into striatal slices only at a high concentration (10-4 M) (Fig. 2) . Each bar is expressed as ng/g wet weight and represents the mean±S.E.M. from 5 separate experiments . *P<0.05, **P<0 .01 represent a significant difference from each control value. (Fig. 3) . In contrast, OM-853 did not affect RC and t1/2 in the rapid phase. Furthermore, it has been found that the high K+ (30 mM) evoked release of [14C]5-HT is also significantly enhanced by the addition of OM-853 (Fig. 3) .
Effect DPAT (10-7 M) alone had no effect on [14C] 5-HT release from the striatal slices (Fig. 6) . Single administration of OM-853 did not induce any changes in the activities of Trp OH and MAO in all brain areas examined. These results suggest that the OM-853 induced enhancement of 5-HT turnover may not be due to the activation of enzymes involved in the synthesis and/or degradation of 5-HT.
It is well-known that the reuptake process plays a significant role in the inactivation of 5-HT which is released into the synaptic cleft. OM-853, however, inhibited [14C] 5-HT uptake in striatal slices only at a high concen tration. Therefore, it is unlikely that the observed acceleration of cerebral 5-HT turnover following OM-853 administration is caused by the inhibition of the uptake processes.
The release of preloaded [14C]5-HT from striatal slices consisted of an initial rapid release phase followed by a slower rate of decline as reported for the release of [3H] GABA in the brain (10) and [3H]dopamine in the retina (16) . It has been generally assumed that the rapid phase of spontaneous release represents the washout of preloaded substance from the extracellular pool, while the slow phase represents its spontaneous release from the intracellular pool, probably that in the neurons (16) . In this study, it has been found that in vitro addition of OM-853 enhances the outflow of [14C]5-HT in the slow phase of the spontaneous release as well as that evoked by high K+. These results suggest that OM-853 may accerelate striatal 5-HT turnover through the augmentation of 5-HT release. It has been well established that presyn aptic autoreceptors are involved in the regulation of the release of several neuro transmitters in the central nervous system (17) . In the case of 5-HT neurons, it has been also reported that presynaptic 5-HT auto receptors modulate the stimulation-evoked release of 5-HT in an inhibitory manner (18, 19) . 8-Hydroxy DPAT is known to act at presynaptic 5-HT autoreceptors as well as 5-HT1A receptors as an agonist. Moreover, presynaptic 5-HT receptors are known to be labeled by [3H]8-hydroxy DPAT (13, 20) . Goodwin and Green (21) also reported that 8-hydroxy DPAT was not only potent in decreasing the rate of synthesis of 5-HT in the brain of the mouse but also in inhibiting the head-twich produced by precursor loading. On the other hand, the hypothermic response in mice to 8-hydroxy DPAT has been reported to be abolished by the lesion of 5-HT-containing nerve terminals and an tagonized by quipazine, which is known to antagonize presynaptic 5-HT function in vitro (22) . In this study, it has been found that OM-853 inhibits [3H]8-hydroxy DPAT binding to 5-HT1A receptors and/or 5-HT autoreceptors, although its inhibitory potency is weaker than that of 5-HT, an endogenous ligand. In contrast, OM-853 showed barely detectable inhibitory actions on [3H] ketanserin binding to 5-HT2 receptors. These results suggest that OM-853 may have a higher affinity for 5-HT,,, receptors and/or presynaptic 5-HT autoreceptors than for 5 HT2 receptors. Considering the facts that the stimulatory effect of OM-853 on 5-HT release was relatively well correlated with its inhibitory potency on [3H]8-hydroxy DPAT binding and the OM-853-induced enhance ment of 5-HT release from striatal slices was antagonized by 8-hydroxy DPAT, it seems likely that OM-853 stimulates 5-HT release from striatal slices via the inhibition of presynaptic 5-HT autoreceptors. However, 8 hydroxy DPAT has been also described as a selective 5-HT1A agonist (23) . Therefore, possible involvement of 5-HT1A receptors in OM-853-induced enhancement of 5-HT release cannot be also excluded.
On the other hand, it has been reported that a-adrenoceptors may modulate 5-HT release in an inhibitory manner (24, 25) . For instance, norepinephrine inhibited [3H]5-HT release from crude synaptosomes obtained from the cerebral cortex, which was an tagonized by (+)mianserin, an a-antagonist. Therefore, possible involvement of a adrenoceptors in the OM-853-induced stimu lation of 5-HT release should be also clarified in future studies.
Nomura et al. reported that the deficiency of L-tryptophan, a precursor of 5-HT, markedly reduced the cerebral contents of 5-HT and 5-HIAA as well as impaired brightness discrimination learning of the operant type (26, 27) . On the other hand, it has been reported that subjects treated with low or high dose of ethanol exhibit impaired memory, particularly in the tests on the recall of poorly learned information and that zimelidine, a relatively specific 5-HT uptake blocker, improves this ethanol-induced im pairment (28) . Winblad et al. reported that the content of monoamines, especially 5-HT, in the cerebral cortex, hippocampus, striatum and hypothalamus showed a decrease in senile dementia and chronic alcoholism (29). These results suggest that the malfunction of 5-HT neurons may be closely related to the disorder of learning and the pathogenesis of senile dementia and chronic alcoholism. In this study, it has been found that OM-853 is likely to exert the enhancing effect on the cerebral turnover of 5-HT by stimulating 5 HT release via the inhibition of presynaptic 5-HT autoreceptors. Therefore, it seems possible that the well-known therapeutic efficacy of OM-853 on various neuro psychiatric disorders such as impairments of psychomotor reaction, complex reaction and concentration in elderly subjects (2) involves the facilitation of 5-HT turnover in the brain.
